O comportamento dos Anofelinos do subgênero Kerteszia, no sul do Brasil e o efeito do inseticida DDT

Informações sobre o comportamento dos Kerteszia obtidas nos Estados de São Paulo, Paraná e Santa Catarina, foram comparadas entre si e com dados relativos a outros anofelinos neotrópicos e etiópicos. Das conclusões obtidas destacam-se: 1. Em seguida ao pôr do sol os Kerteszia tornam-se mais ativos nas copas das árvores da mata a ao anoitecer, quando começam a se inverter as diferenças microclimáticas existentes entre a floresta e ao ar livre, passam a predominar nas áreas abertas; 2. nas localidades não dedetizadas não existe grande diferença entre a proporção dos Kerteszia que se alimenta dentro das casas e a que tem sido observada para o A. gambiae, na África. Entretanto, memso antes do aparecimento do DDT, os Kerteszia não eram mosquitos endófilos. Para os anofelinos ditos zoófilos, como o A. strodei, a relação entre o número de mosquitos capturados simultaneamente no peridomicílio e dentro de casa, é pelo menos duas vezes mais elevada; 3. Alguns dados sobre a ação impedidora ('deterrency") do DDT, para os kerteszia, mostram que ela é elevadíssima, outros são da mesma ordem de grandeza dos observados para o A. gambiae. Foi verificado que os Kerteszia evitam entrar mesmo em casas com muito pouco inseticida; 4. Apenas uma pequena proporção dos Kerteszia, que se alimenta dentro das casas, pousa nas paredes; a maioria voa diretamente para as pessoas e depois para fora. O tempo de permanência nas superfícies dedetizadas é o mesmo que tem sido observado para outros anofelinos, geralmente inferior a 10 minutos; 5. Ao contrário da maioria dos transmissores de malária a atividade dos Kerteszia, fora da mata, concentra-se nas primeiras horas da noite, quando há maior probabilidade de existir pessoas fora de casa; 6. o estudo do contato homem-mosquito ("man-bitting rate") mostrou que, mesmo nas casas não dedetizadas, esse contato é quase sempre maior fora dos domicilios. Nas localidades dedetizadas a componente externa, desse contato, pode ser até 10 vezes mais elevada. O que, logicamente, resulta do horário de atividade; 7. Os trabalhos de profilaxia do antigo Serviços Nacional de Malária já haviam mostrado que, mesmo com distribuição de medicamentos, essa diminuição dos contatos homem-mosquito dentro das casas e a ação tóxica do inseticida, são suficientes para impedir a transmissão da malária. Fato que, juntamente com os dados das capturas extradomiciliares, sugere a realização de pesquisas visando encontrar medidas capazes de diminuir a densidade dos kerteszia nas áreas freqüentadas pela população humana.

Alterações celulares na glândula pineal de ratas albinas: efeito da estimulação sonora diária

Foi observado haver uma relação entre o estímulo sonoro intenso e alterações morfológicas na glândula (g.l) pineal de ratas adultas. Estes animais foram estimulados por uma campainha elétrica, com nível de intensidade sonora em torno de 110 db, por 1, 2, 4 e 7 dias e como também por mais 10 estímulos sucessivos no sétimo dia. Foram observadas alterações celulares, tais como: núcleos picnóticos, vacuolizações e perda do aspecto lobular da distribuição dos pinealócitos, sendo que estas alterações se agravam com o aumento do número de estimulações.

Regulação da resposta blastogênica mediada por antígeno anticorpo específico: I - efeito de complexos imunes pré-formados na resposta proliferativa de linfócitos

Estudos prévios em animais de experimentação têm mostrado que complexos imunes formados por antígeno e anticorpo exercem uma influência reguladora na resposta proliferativa de linfócitos. utilizando-se de indivíduos previamente imunizados ou não com Keyhole Limpet Hemocyanin (KLH) o presente trabalho compara a resposta blastogênica induzida pelo antígeno (KLH) com aquela induzida por complexos imunes sob a forma de precipitado constituídos por KLH e IgG anti-KLH. Em cultura de linfócitos de indivíduos previamente imunizados, complexos formados por KLH e IgG anti-KLH induziram in vitro uma resposta proliferativa significantemente maior que o antígeno. Este aumento da bastogênese verificado quando o anticorpo foi acoplado ao antígeno não dependeu da presença de complemento, da quantidade de moléculas do anticorpo no complexo, foi específico com relação ao antígeno pois não houve bastogênese significante em cultura de linfócitos de indivíduos não imunizados, quando estimulados com complexos de KLH e IgG anti-KLH. Linfócitos que não são nem T nem B mas possuem receptor Fc para moléculas de IgG desempenham papel importante na resposta mediado por complexos imunes, haja vista a depleção destes linfócitos reduziu a resposta proliferativa mediada por complexos imunes à observada com o antígeno isoladamente.

Efeito da esquistossomose na produtividade do cortador de cana ao longo da safra de açúcar da usina catende, Pernambuco

Estudo prospectivo de pareamento entre dois grupos de trabalhadores do corte de cana infectados com esquistossomose na zona da mata do Estado de Pernambuco, foi realizado durante a safra de 1977-1978. O grupo de "casos" (forma hepatosplénica) foi comparado com o grupo "controle" (forma intestinal). Os resultados mostraram não apenas que os portadores da forma hepatosplénica cortavam significativamente menos cana que seus controles, como também que a produção daqueles mantinha-se baixa ao longo da safra. Dois trabalhadores, dentre os "casos", tiveram que abandonar o trabalho de campo em vista da visível deterioração de seu estado geral de saúde.

Efeito da dieta láctea na supressão da parasitemia e no desenvolvimento da imunidade humoral durante o curso da infecção malárica em camundongos

Estudou-se o efeito da dieta láctea, por um período de 150 dias em camundongos infectados com diferentes números das formas sangüíneas de Plasmodium berghei, e observou-se o desenvolvimento da imunidade humoral nestes animais pela dosagem das imunoglobulinas das classes IgG e IgM no soro, usando o teste de imunofluorescência indireta. Os resultados indicam que a administração do leite, como único alimento em camundongos, protege-os cotnra infecção malárica fatal, independentemente do número de parasitas inoculados. Os animais desenvolveram altos níveis de anticorpos IgG, os quais persistiram no soro por longo período de tempo. Contudo, os anticorpos IgM somente foram detectáveis no soro durante as primeiras duas semanas de infecção. O P. berghei continua presente na circulação periférica, após dois meses de infecção, uma vez que o sangue destes animasi inoculados em camundongos mantidos em dieta norma, produziu infecção fatal nos recipientes. No entanto, ao exame microscópico não foi possível detectar o parasita da malária no sangue periférico destes animais. O protozoário esteve presente no baço e fígado dos camundongos durante todo o tempo de duração da pesquisa. A presença contínua do P. berghei nestes animais, em nível de infecção subclínica, ofereceu ao hospedeiro o desenvolvimento de uma imunidade sólida contra subseqüente infecção. Esta imunidade adquirida esteve presente, nestes animais, até cinco meses após a infecção.

Men perform comparably to women in a perspective taking task after administration of intranasal oxytocin but not after placebo

Oxytocin (OT) is thought to play an important role in human interpersonal information processing and behavior. By inference, OT should facilitate empathic responding, i.e. the ability to feel for others and to take their perspective. In two independent double-blind, placebo-controlled between-subjects studies, we assessed the effect of intranasally administered OT on affective empathy and perspective taking, whilst also examining potential sex differences (e.g., women being more empathic than men). In study 1, we provided 96 participants (48 men) with an empathy scenario and recorded self reports of empathic reactions to the scenario, while in study 2, a sample of 120 individuals (60 men) performed a computerized implicit perspective taking task. Whilst results from Study 1 showed no influence of OT on affective empathy, we found in Study 2 that OT exerted an effect on perspective taking ability in men. More specifically, men responded faster than women in the placebo group but they responded as slowly as women in the OT group. We conjecture that men in the OT group adopted a social perspective taking strategy, such as did women in both groups, but not men in the placebo group. On the basis of results across both studies, we suggest that self-report measures (such as used in Study 1) might be less sensitive to OT effects than more implicit measures of empathy such as that used in Study 2. If these assumptions are confirmed, one could infer that OT effects on empathic responses are more pronounced in men than women, and that any such effect is best studied using more implicit measures of empathy rather than explicit self-report measures.

Efeito da quimioterapia sobre os ovos do Schistosoma mansoni

A administração de praziquantel a camundongos infectados pelo Schistosoma mansoni (50 cercarias/8 semanas) causou necrose de coagulação e/ou lítica, e por vezes calcificação dos miracídios nos tecidos a partir do 4º dia do início do tratamento. A administração conjugada de oxamniquine/hycanthone, embora muito efetiva para eliminar os vermes adultos, não teve ação sobre os miracídios no interior dos granulomas, tendo os testes de eclosão sido positivos até o 15º dia após o tratamento curativo. A ação do praziquantel sobre os ovos do S. mansoni pode ter repercussão sorológica ou patogênica, facilitando uma mais rápida reabsorção dos granulomas pelos tecidos do hospedeiro.

Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.

Recent studies have demonstrated the immunomodulatory properties of vitamin D, and vitamin D deficiency may be a risk factor for the development of MS. The risk of developing MS has, in fact, been associated with rising latitudes, past exposure to sun and serum vitamin D status. Serum 25-hydroxyvitamin D [25(OH)D] levels have also been associated with relapses and disability progression. The identification of risk factors, such as vitamin D deficiency, in MS may provide an opportunity to improve current treatment strategies, through combination therapy with established MS treatments. Accordingly, vitamin D may play a role in MS therapy. Small clinical studies of vitamin D supplementation in patients with MS have reported positive immunomodulatory effects, reduced relapse rates and a reduction in the number of gadolinium-enhancing lesions. However, large randomized clinical trials of vitamin D supplementation in patients with MS are lacking. SOLAR (Supplementation of VigantOL(®) oil versus placebo as Add-on in patients with relapsing-remitting multiple sclerosis receiving Rebif(®) treatment) is a 96-week, three-arm, multicenter, double-blind, randomized, placebo-controlled, Phase II trial (NCT01285401). SOLAR will evaluate the efficacy of vitamin D(3) as add-on therapy to subcutaneous interferon beta-1a in patients with RRMS. Recruitment began in February 2011 and is aimed to take place over 1 calendar year due to the potential influence of seasonal differences in 25(OH)D levels.

Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial.

INTRODUCTION: Two subcutaneous injections of adalimumab in severe acute sciatica significantly reduced the number of back operations in a short-term randomised controlled clinical trial. OBJECTIVE: To determine in a 3-year follow-up study whether the short-term benefit of adalimumab in sciatica is sustained over a longer period of time. METHODS: The primary outcome of this analysis was incident discectomy. Three years after randomisation, information on surgery could be retrieved in 56/61 patients (92%).A multivariate Cox proportional hazard models, adjusted for potential confounders, was used to determine factors predisposing to surgery. RESULTS: Twenty-three (41%) patients had back surgery within 3 years, 8/29 (28%) in the adalimumab group and 15/27 (56%) in the placebo group, p=0.04. Adalimumab injections reduced the need for back surgery by 61% (HR)=0.39 (95% CI 0.17 to 0.92). In a multivariate model, treatment with a tumour necrosis factor-α antagonist remained the strongest protective factor (HR=0.17, p=0.002). Other significant predictors of surgery were a good correlation between symptoms and MRI findings (HR=11.6, p=0.04), baseline intensity of leg pain (HR=1.3, p=0.06), intensity of back pain (HR=1.4, p=0.03) and duration of sickness leave (HR=1.01 per day, p=0.03). CONCLUSION: A short course of adalimumab in patients with severe acute sciatica significantly reduces the need for back surgery.

Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial.

OBJECTIVE: To determine the subjective response to iron therapy in non-anaemic women with unexplained fatigue. DESIGN: Double blind randomised placebo controlled trial. SETTING: Academic primary care centre and eight general practices in western Switzerland. PARTICIPANTS: 144 women aged 18 to 55, assigned to either oral ferrous sulphate (80 mg/day of elemental iron daily; n=75) or placebo (n=69) for four weeks. MAIN OUTCOME MEASURES: Level of fatigue, measured by a 10 point visual analogue scale. RESULTS: 136 (94%) women completed the study. Most had a low serum ferritin concentration; <or= 20 microg/l in 69 (51%) women. Mean age, haemoglobin concentration, serum ferritin concentration, level of fatigue, depression, and anxiety were similar in both groups at baseline. Both groups were also similar for compliance and dropout rates. The level of fatigue after one month decreased by -1.82/6.37 points (29%) in the iron group compared with -0.85/6.46 points (13%) in the placebo group (difference 0.95 points, 95% confidence interval 0.32 to 1.62; P=0.004). Subgroups analysis showed that only women with ferritin concentrations <or= 50 microg/l improved with oral supplementation. CONCLUSION: Non-anaemic women with unexplained fatigue may benefit from iron supplementation. The effect may be restricted to women with low or borderline serum ferritin concentrations.

Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.

BACKGROUND: Classically, clinical trials are based on the placebo-control design. Our aim was to analyze the placebo effect in Huntington's disease. METHODS: Placebo data were obtained from an international, longitudinal, placebo-controlled trial for Huntington's disease (European Huntington's Disease Initiative Study Group). One-hundred and eighty patients were evaluated using the Unified Huntington Disease Rating Scale over 36 months. A placebo effect was defined as an improvement of at least 50% over baseline scores in the Unified Huntington Disease Rating Scale, and clinically relevant when at least 10% of the population met it. RESULTS: Only behavior showed a significant placebo effect, and the proportion of the patients with placebo effect ranged from 16% (first visit) to 41% (last visit). Nondepressed patients with better functional status were most likely to be placebo-responders over time. CONCLUSIONS: In Huntington's disease, behavior seems to be more vulnerable to placebo than overall motor function, cognition, and function

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.

BACKGROUND: Hypertension can be controlled adequately with existing drugs such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Nevertheless, treatment success is often restricted by patients not adhering to treatment. Immunisation against angiotensin II could solve this problem. We investigated the safety and efficacy of CYT006-AngQb-a vaccine based on a virus-like particle-that targets angiotensin II to reduce ambulatory blood pressure. METHODS: In this multicentre, double-blind, randomised, placebo-controlled phase IIa trial, 72 patients with mild-to-moderate hypertension were randomly assigned with a computer-generated randomisation list to receive subcutaneous injections of either 100 mug CYT006-AngQb (n=24), 300 mug CYT006-AngQb (24), or placebo (24), at weeks 0, 4, and 12. 24-h ambulatory blood pressure was measured before treatment and at week 14. The primary outcomes were safety and tolerability. Analyses were done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00500786. FINDINGS: Two patients in the 100 mug group, three in the 300 mug group, and none in the placebo group discontinued study treatment. All patients were included in safety analyses; efficacy analyses did not include the five dropouts, for whom no data were available at week 14. Five serious adverse events were reported (two in the 100 mug group, two in the 300 mug group, and one in the placebo group); none were deemed to be treatment related. Most side-effects were mild, transient reactions at the injection site. Mild, transient influenza-like symptoms were seen in three patients in the 100 mug group, seven in the 300 mug group, and none in the placebo group. In the 300 mug group, there was a reduction from baseline in mean ambulatory daytime blood pressure at week 14 by -9.0/-4.0 mm Hg compared with placebo (p=0.015 for systolic and 0.064 for diastolic). The 300 mug dose reduced the early morning blood-pressure surge compared with placebo (change at 0800 h -25/-13 mm Hg; p<0.0001 for systolic, p=0.0035 for diastolic). INTERPRETATION: Immunisation with CYT006-AngQb was associated with no serious adverse events; most observed adverse events were consistent with local or systemic responses similar to those seen with other vaccines. The 300 mug dose reduced blood pressure in patients with mild-to-moderate hypertension during the daytime, especially in the early morning. FUNDING: Cytos Biotechnology AG.

Perfusion-CT guided intravenous thrombolysis in patients with unknown-onset stroke: a randomized, double-blind, placebo-controlled, pilot feasibility trial.

INTRODUCTION: Patients with unknown stroke onset are generally excluded from acute recanalisation treatments. We designed a pilot study to assess feasibility of a trial of perfusion computed tomography (PCT)-guided thrombolysis in patients with ischemic tissue at risk of infarction and unknown stroke onset. METHODS: Patients with a supratentorial stroke of unknown onset in the middle cerebral artery territory and significant volume of at-risk tissue on PCT were randomized to intravenous thrombolysis with alteplase (0.9 mg/kg) or placebo. Feasibility endpoints were randomization and blinded treatment of patients within 2 h after hospital arrival, and the correct application (estimation) of the perfusion imaging criteria. RESULTS: At baseline, there was a trend towards older age [69.5 (57-78) vs. 49 (44-78) years] in the thrombolysis group (n = 6) compared to placebo (n = 6). Regarding feasibility, hospital arrival to treatment delay was above the allowed 2 h in three patients (25%). There were two protocol violations (17%) regarding PCT, both underestimating the predicted infarct in patients randomized in the placebo group. No symptomatic hemorrhage or death occurred during the first 7 days. Three of the four (75%) and one of the five (20%) patients were recanalized in the thrombolysis and placebo group respectively. The volume of non-infarcted at-risk tissue was 84 (44-206) cm(3) in the treatment arm and 29 (8-105) cm(3) in the placebo arm. CONCLUSIONS: This pilot study shows that a randomized PCT-guided thrombolysis trial in patients with stroke of unknown onset may be feasible if issues such as treatment delays and reliable identification of tissue at risk of infarction tissue are resolved. Safety and efficiency of such an approach need to be established.